Senescence in Chronic Kidney Disease

Part of paid clinical trials in Jacksonville, Florida.

Sponsor
Mayo Clinic
Study ID
NCT02848131
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Group 2: Dasatinib — DRUG
    Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.
  • Group 2: Quercetin — DRUG
    Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.

Study Details

The study goal is to assess the effect of senescent cell clearance on senescence burden, physical ability or frailty, and adipose tissue-derived mesenchymal stem cell (MSC) functionality in patients with chronic kidney disease (CKD).

Key Dates

Start date
Jul 31, 2016
Status verified
May 2026
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • No Intervention: Group 1: Observational
    Observational Only
  • Active Comparator: Group 2: Dasatinib & Quercetin
    The drugs dasatinib and quercetin will be used in this arm

Primary Outcome Measure

Change in proportion of senescent cells (representing the total senescent cell burden) present [ Time Frame: Baseline, Day 14 ]

Locations (2)

FacilityCityStateZIPSite coordinators
Mayo Clinic FloridaJacksonvilleFlorida32224-
Mayo Clinic in RochesterRochesterMinnesota55905-

Find similar trials in Jacksonville, FL

By condition
Chronic kidney disease
By specialty
NephrologyKidney disease
By research site
Mayo Clinic Florida· Jacksonville, FLMayo Clinic in Rochester· Rochester, MN

Related Studies